Live feed07:00:00·1137dPRReleasevia QuantisnowImmatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMEByQuantisnow·Wall Street's wire, on your screen.IMTX· Immatics N.V.Health Care
